1春节期间医药行业重点事件梳理1.1创新药BD交易实现开门红,优势产品海外研发和注册进展顺利2026年春节前后,中国创新药对外BD交易实现开门红,全年交易金额有望再攀新高。1)2月11日,瑞博生物与全球制药企业Madrigal Pharmaceuticals达成全球独家许可协议,基于瑞博生物自主研发的肝靶向RiboGalSTAR平台,合作开发六款针对代谢功能障碍相关脂肪性肝炎(MASH)的临床前...
Source Link1春节期间医药行业重点事件梳理1.1创新药BD交易实现开门红,优势产品海外研发和注册进展顺利2026年春节前后,中国创新药对外BD交易实现开门红,全年交易金额有望再攀新高。1)2月11日,瑞博生物与全球制药企业Madrigal Pharmaceuticals达成全球独家许可协议,基于瑞博生物自主研发的肝靶向RiboGalSTAR平台,合作开发六款针对代谢功能障碍相关脂肪性肝炎(MASH)的临床前...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.